Inventor · disambiguated record
Eric Furfine
Also filed as: FURFINE ERIC · FURFINE ERIC S · FURFINE ERIC STEVEN
51 granted patents·23 pending applications·1,331 citations·filing 1994–2025
99Inventor score
Files withVERTEX PHARMA19REGENERON PHARMA16OHANA BIOSCIENCES INC8BRISTOL MYERS SQUIBB CO7GLAXO WELLCOME INC4
Top patents by PatentIndex Score
74 records- 0199US11084865B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2020·Granted Aug 10, 2021·14 cites·64 claims
- 0299US10464992B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Nov 5, 2019·60 cites·18 claims
- 0399US10400025B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Sep 3, 2019·54 cites·15 claims
- 0499US9914763B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Mar 13, 2018·56 cites·12 claims
- 0599US9580489B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Feb 28, 2017·67 cites·29 claims
- 0699US9340594B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2014·Granted May 17, 2016·73 cites·12 claims
- 0799US8802107B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2013·Granted Aug 12, 2014·65 cites·18 claims
- 0899US7807164B2Lyophilized VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2009·Granted Oct 5, 2010·83 cites·9 claims
- 0998US11066458B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2019·Granted Jul 20, 2021·12 cites·66 claims
- 1098US8481046B2VEGF antagonist formulations for intravitreal administrationFURFINE ERIC·Filed 2011·Granted Jul 9, 2013·72 cites·9 claims
- 1198US8092803B2VEGF antagonist formulations for intravitreal administrationFURFINE ERIC·Filed 2010·Granted Jan 10, 2012·136 cites·19 claims
- 1297US11732024B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2021·Granted Aug 22, 2023·2 cites·60 claims
- 1397US7608261B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMACUTICALS INC·Filed 2007·Granted Oct 27, 2009·131 cites·17 claims
- 1497US6319946B1Inhibitors of aspartyl proteaseVERTEX PHARMA·Filed 2000·Granted Nov 20, 2001·88 cites·22 claims
- 1596US8221765B2Multivalent fibronectin based scaffold domain proteinsCAMPHAUSEN RAY·Filed 2009·Granted Jul 17, 2012·66 cites·20 claims
- 1695US12331099B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2024·Granted Jun 17, 2025·0 cites·30 claims
- 1795US9902762B2Multivalent fibronectin based scaffold domain proteinsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Feb 27, 2018·28 cites·10 claims
- 1895US8728483B2Multivalent fibronectin based scaffold domain proteinsCAMPHAUSEN RAY·Filed 2012·Granted May 20, 2014·38 cites·29 claims
- 1994US9540424B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jan 10, 2017·27 cites·19 claims
- 2094US8969289B2Serum albumin binding moleculesGOSSELIN MICHAEL L·Filed 2011·Granted Mar 3, 2015·45 cites·33 claims
- 2194US7531172B2Methods of treating diseases with a VEGF antagonistREGENERON PHARMA·Filed 2006·Granted May 12, 2009·30 cites·10 claims
- 2294US6811780B2Methods of using cytokine antagonists to treat HIV infection and AIDSREGENERON PHARMA·Filed 2003·Granted Nov 2, 2004·49 cites·13 claims
- 2393US10221438B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 5, 2019·12 cites·16 claims
- 2492US10774130B2Method of treating cancer by administering multivalent fibronectin based scaffold domain proteinsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Sep 15, 2020·6 cites·15 claims
- 2591US10934572B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 2, 2021·4 cites·16 claims
- 2691US6613743B2Sulfonamide inhibitors of aspartyl proteaseVERTEX PHARMA·Filed 2000·Granted Sep 2, 2003·24 cites·25 claims
- 2790US10470798B1Methods for promoting fertilizationOHANA BIOSCIENCES INC·Filed 2019·Granted Nov 12, 2019·8 cites·20 claims
- 2890US2023374108A1Vegf antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2989US10711050B2Variant serum albumin with improved half-life and other propertiesALBUMEDIX LTD·Filed 2018·Granted Jul 14, 2020·6 cites·33 claims
- 3087US2025257118A1Vegf antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3184US6559137B1Sulphonamide derivatives as prodrugs of aspartyl protease inhibitorsVERTEX PHARMA·Filed 2000·Granted May 6, 2003·17 cites·41 claims
- 3282US9951130B2IL-6 antagonists and uses thereofELEVEN BIOTHERAPEUTICS INC·Filed 2014·Granted Apr 24, 2018·7 cites·20 claims
- 3381US8388963B2Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereofVRIGNAUD PATRICIA·Filed 2009·Granted Mar 5, 2013·7 cites·14 claims
- 3479US7419967B2Sulfonamide inhibitors of aspartyl proteaseVERTEX PHARMA·Filed 2005·Granted Sep 2, 2008·2 cites·13 claims
- 3578US10603075B1Compositions and methods for enhancing sperm functionOHANA BIOSCIENCES INC·Filed 2019·Granted Mar 31, 2020·1 cites·21 claims
- 3677US2025059270A1Il-6 antibodiesHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 3776US8455497B2Inhibitors of aspartyl proteaseHALE MICHAEL R·Filed 2009·Granted Jun 4, 2013·2 cites·40 claims
- 3875US6838474B2Sulphonamide derivatives as prodrugs of aspartyl protease inhibitorsVERTEX PHARMA·Filed 2003·Granted Jan 4, 2005·6 cites·12 claims
- 3974US12331334B2Modified urokinase-type plasminogen activator polypeptides and methods of useVERTEX PHARMA·Filed 2023·Granted Jun 17, 2025·0 cites·65 claims
- 4074US6617350B2Inhibitors of aspartyl proteaseVERTEX PHARMA·Filed 2001·Granted Sep 9, 2003·5 cites·22 claims
- 4172US6878728B1Inhibitors of aspartyl proteaseVERTEX PHARMA·Filed 2000·Granted Apr 12, 2005·7 cites·20 claims
- 4271US6225305B1Substituted urea and isothiorea derivatives as no synthase inhibitorsGLAXO WELLCOME INC·Filed 2000·Granted May 1, 2001·3 cites·5 claims
- 4370US2021017252A1Multivalent fibronectin based scaffold domain proteinsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 4467US2010124543A1Sulphonamide derivatives as prodrugs of aspartyl protease inhibitorsVERTEX PHARMA·Filed 2009·Application pending·0 cites
- 4566US2025136965A1Complement factor i-related compositions and methodsVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 4666US2025263683A1Modified urokinase-type plasminogen activator polypeptides and methods of useVERTEX PHARMA·Filed 2025·Application pending·0 cites
- 4764US7592368B2Sulphonamide derivatives as prodrugs of aspartyl protease inhibitorsVERTEX PHARMA·Filed 2004·Granted Sep 22, 2009·1 cites·20 claims
- 4862US7919523B2Inhibitors of aspartyl proteaseVERTEX PHARMA·Filed 2008·Granted Apr 5, 2011·0 cites·20 claims
- 4962US6297276B1Substituted urea and isothiourea derivatives as no synthase inhibitorsGLAXOSMITHKLINE·Filed 2001·Granted Oct 2, 2001·3 cites·2 claims
- 5061US2020170674A1Compositions and methods for enhancing sperm functionOHANA BIOSCIENCES INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →